VIA
BBIO icon

Virtus Investment Advisers’s BridgeBio Pharma BBIO Stock Holding History

Virtus Investment Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
17,408
+6,174
+55% +$432K 0.3% 154
2026
Q1 		$834K Buy
11,234
+2,141
+24% +$155K 0.23% 159
2025
Q4 		$696K Sell
9,093
-2,115
-19% -$139K 0.19% 167
2025
Q3 		$582K Hold
11,208
– – 0.17% 191
2025
Q2 		$484K Sell
11,208
-1,770
-14% -$64.4K 0.16% 186
2025
Q1 		$449K Buy
+12,978
New +$438K 0.12% 202

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Virtus Investment Advisers's BBIO Position: Q2 2026 in Review

Virtus Investment Advisers increased its BridgeBio Pharma (BBIO) stake by 55% in Q2 2026, buying an estimated $432K and bringing the position to 17,408 shares worth $1.3M. The position accounts for 0.3% of the portfolio, ranked #154.

Virtus Investment Advisers first reported a position in BBIO in Q1 2025 and has held it in 6 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Virtus Investment Advisers held 17,408 shares of BridgeBio Pharma worth $1.3M as of Q2 2026.
  • Virtus Investment Advisers bought 6,174 BridgeBio Pharma shares in Q2 2026, an estimated $432K.
  • BridgeBio Pharma made up 0.3% of Virtus Investment Advisers's portfolio in Q2 2026, its #154 holding.
  • Virtus Investment Advisers first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 6 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.